Advertisement

Drugs

, Volume 76, Issue 12, pp 1227–1232 | Cite as

Atezolizumab: First Global Approval

  • Anthony Markham
AdisInsight Report
Part of the following topical collections:
  1. Topical Collection on Immuno-Oncology

Abstract

Atezolizumab (Tecentriq™)—a monoclonal antibody targeting programmed death ligand 1 (PD-L1 or CD274 antigen)—is being developed by Genentech as treatment for a variety of haematological malignancies and solid tumours. It been approved in the US as a second-line therapy for urothelial carcinoma and is awaiting approval as a second-line therapy for non-small cell lung cancer. This article summarizes the milestones in the development of atezolizumab leading to this first approval for urothelial carcinoma.

Keywords

Docetaxel Objective Response Rate Pemetrexed Urothelial Carcinoma Metastatic Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis, Springer SBM.

References

  1. 1.
    FDA. FDA approves new, targeted treatment for bladder cancer [media release]. 6 Jun 2016. http://www.fda.gov.
  2. 2.
    Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Genentech Inc. Prescribing information for Tecentriq™ (atezolizumab) injection, for intravenous use. 2016. http://www.gene.com/download/pdf/tecentriq_prescribing.pdf. Accessed 20 May 2016.
  4. 4.
    Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Petrylak DP, Powles T, Bellmunt J, et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC) [abstract no. 4501]. J Clin Oncol. 2015;33(Suppl).Google Scholar
  6. 6.
    Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Besse B, Johnson M, Janne PA, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) [abstract no. 16LBA]. Eur J Cancer. 2015;51(Suppl 3):S717–8.CrossRefGoogle Scholar
  8. 8.
    Spigel DR, Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) [abstract no. 8028]. J Clin Oncol. 2015;33(Suppl).Google Scholar
  9. 9.
    Camidge R, Liu SV, Powderly J, et al. Atezolizumab (MPDL3280A) combined with platinum-based chemotherapy in non-small cell Lung cancer (NSCLC): a phase Ib safety and efficacy update [abstract no. ORAL02.07]. J Thorac Oncol. 2015;10(9 Suppl 2):S176–7.Google Scholar
  10. 10.
    Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) [abstract no. 2859]. Cancer Res. 2015;75(15 Suppl).Google Scholar
  11. 11.
    Adams S, Diamond J, Hamilton E, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer [abstract no. P2-11-06]. Cancer Res. 2016;76(4 Suppl).Google Scholar
  12. 12.
    McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;10(34):833–42.CrossRefGoogle Scholar
  13. 13.
    Sznol M, McDermott DF, Jones SF, et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract no. 410]. J Clin Oncol. 2015;33(Suppl 7).Google Scholar
  14. 14.
    Bendell J, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC) [abstract no. 3502]. J Clin Oncol. 2016;34(Suppl).Google Scholar
  15. 15.
    Boyd Z, Smith D, Baker B, et al. Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab [abstract no. B001]. Cancer Immunol Res. 2016;4(Suppl).Google Scholar
  16. 16.
    Castellano D, Albers P, Gschwend JE, et al. A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010) [abstract]. Eur Urol. 2016;15(3 Suppl).Google Scholar
  17. 17.
    Herbst RS, De Marinis F, Jassem J, et al. Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1-selected chemotherapy-naive patients with advanced NSCLC [abstract no. 355TiP]. Ann Oncol. 2015;26(Suppl 9):i105–6.Google Scholar
  18. 18.
    Mok TSK, Cappuzzo F, Jotte RM, et al. Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC [abstract no. 356TiP]. Ann Oncol. 2015;26(Suppl 9):ix106.CrossRefGoogle Scholar
  19. 19.
    Rizvi NA, Chow LQM, Dirix LY, et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC) [abstract no. TPS8123]. J Clin Oncol. 2014;32(5 Suppl).Google Scholar
  20. 20.
    Emens L, Adams S, Loi S, et al. A phase III randomized trial of atezolizumab in combination with nab- paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) [abstract no. OT1-01-06]. Cancer Res. 2015;76(4 Suppl).Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations